Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

OP2DRAIN To deliver the first medical treatment dedicated to patients with haemorrhagic stroke

Coordinator
Op2Lysis, France
Runs
1 July 2022 to 30 June 2024
Status
Running
EU funding
€2.5m
Total cost
€10.5m
Partners
2 organisations in 2 countries
Type
European Innovation Council
Grant agreement
190188714

What the project is doing

In the project's own words, from its summary on CORDIS.

The NANOp2lysis platform is a deep-tech technology to protect active enzymes by a reversible precipitation and to produce solid-state nanoparticles. Such particles can then be loaded at high concentration into tailored carrier (with specific targeting / slow delivery characteristics). O2L-001 (derived from NANOp2Lysis) is the first effective and safe treatment to remove intracerebral hematoma and reduce disability and death following acute hemorrhagic stroke (AHS).

It has been tailored to be locally injected, after micro-invasive surgery, via a catheter at the core of the hematoma. The in vivo gelation of the product at body temperature allows a local and slow delivery of our new thrombolytic agent, OptPA. The main characteristics of O2L-001 are thus the following:-EASY. simplified model of administration (unique injection) -EFFICIENT. better thrombolytic effect on best translational model (vs gold standard)-SAFE. reduced side effect (bleeding and neurotoxoxicity vs gold standard)

Topics

Who is involved

OrganisationCityCountryRole
Op2LysisBoulogne-BillancourtFranceCoordinator
Op2lysis DevelopmentHerstalBelgiumThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI